Antibody Drug Conjugate (ADC) Market

We are aware that various second and third generation ADCs that are being developed by different companies, have shown significant improvements, in terms of clinical results, compared to traditional ADCs. As a result, novel ADC technologies have garnered the attention of physicians, patients and their families, having demonstrated improved clinical outcomes. We are optimistic about the growth of the ADCs market and believe that competition in this domain is likely to increase in the future.

- Executive Director / Chief Innovation Officer, a big pharma company

Global Antibody Drug Conjugate (ADC) Market Size

The global antibody drug conjugate (ADC) market, valued at USD 15.29 billion in 2025, is projected to reach USD 18.69 billion in 2026 and USD 28.41 billion by 2035, representing a CAGR of 4.8% during the forecast period 2026 to 2035. Antibody drug conjugates are engineered therapeutics with monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers.

Over the years, various technological advancements, such as antibody discovery / engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for ADCs to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. 

To learn more about this report, request a free sample copy

To date, 19 antibody-drug conjugates have been approved by the USFDA and other regulatory bodies for therapeutic use, namely Adcetris, Aidixi, Akalux, Besponsa, Blenrep, Datroway, Elahere, Emrelis, Enhertu, Jiataile, Kadcyla, Lumoxiti, Mylotarg, Padcev, Polivy, Tivdak, Trastuzumab Rezetecan, Trodelvy and Zynlonta.

The success of these ADC therapeutics can be attributed to their high tumor selectivity and potent cytotoxic capabilities, which help minimize off-target toxicities. Further, the promising clinical trial outcomes, especially intended to target solid tumors, continue to receive strong support from various investors. Given the ongoing pace of innovation, the ADC market is likely to witness significant growth during the forecast period.

Antibody Drug Conjugate Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2023
Forecast Period	Till 2035
Market Size 2026	$ 18.69 Billion
Market Size 2035	$ 28.41 Billion
CAGR (Till 2035)	4.8%

The antibody drug conjugate market analysis also features the likely distribution of the current and forecasted opportunity within the adc pharmaceutical domain across various segments, such as target indication, therapeutics area, linker, payload, target antigen and key geographical regions.

We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.

Recent advancements in biotechnology, including site-specific conjugation, novel linker technologies, and innovative payloads, are enhancing ADC efficacy and safety, fueling innovation in targeted cancer therapies. Further, the rising prevalence of oncological disorders, with millions of new cases annually, is driving the increasing demand for precision medicine, particularly for oncology. This demand is fueled by ADCs’ ability to deliver cytotoxic ADC payload / warheads directly to cancer cells, minimizing damage to healthy tissues. Coupled with increased R&D expenditure in the pharmaceutical industry, these factors are propelling the demand for ADCs. In addition, this surge is supporting the development of next-generation ADCs, addressing challenges like drug resistance and toxicity.

Recent Developments in Antibody Drug Conjugate Market

Several recent developments in the field of antibody drug conjugates have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall antibody drug conjugate market trends detailed in our analysis.

• In June 2025, Sanyou Biopharmaceuticals signed an agreement with Medicovestor to develop innovative first-in-class chemoimmunotherapy antibody-drug conjugates for the treatment of oncology and autoimmune diseases.
• In June 2025, Kivu Bioscience partnered with Sterling Pharma Solutions to manufacture cGMP clinical material for KIVU-107, a next-generation antibody-drug conjugate for Phase 1 oncology trials.
• In June 2025,SK plasma signed a joint development and licensing agreement with antibody-drug conjugate (ADC) specialist AIMEDBIO to co-develop next generation targeted cancer therapy.

Antibody Drug Conjugate (ADC) Market Segmentation Insights

The market research report presents an in-depth analysis of the various ADC therapeutics, across different segments, as defined in the table below:

Antibody Drug Conjugates Market: Market Segmentations

Market Segmentations	Details
Target Indication	Breast Cancer Lung Cancer B-Cell Lymphoma Multiple Myeloma Ovarian Cancer Renal Cancer Gastric Cancer Hodgkin's Lymphoma Other Target Indications
Therapeutic Area	Solid Tumors Hematological Cancer
Linker	Tetrapeptide-based Linker Valine-Citrulline SMCC Maleimidocaproyl Maleimide Sulfo-SPDB Tetrapeptide-Maleimide-Linker GGFG (Peptide) Linker Other Linkers
Payload	Monomethyl Auristatin E (MMAE) Camptothecin Exatecan DM1 Monomethyl Auristatin F (MMAF) SN-38 / Irinotecan DM4 Other Payloads
Target Antigen	HER-2 (ERBB2) TROP-2 CD79b BCMA (TNFRSF17 / BCM) FOLR1 (Folate receptor alpha) c-MET Nectin 4 CD30 Integrin beta-6 Other Target Antigens
Market in North America	US Canada
Market in Europe	Germany France UK Italy Spain
Market in Asia-Pacific and Rest of the World	China Japan Australia

Industry Experts on Antibody Drug Conjugates (ADC) Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The ADC market report includes detailed transcripts of interviews conducted with the following individuals (arranged in decreasing order of seniority level):

• Founder and Chief Executive Officer, Mid-sized Company, UK
• Founder and Chief Executive Officer, Small Company, US
• Co-Founder and Chief Executive Officer, Small Company, France
• President and Chief Executive Officer, Large Company, Italy
• Former Chief Executive Officer, Large Company, US
• Founder and Chief Executive Officer, Small Company, US
• Chief Business Officer and Head of Strategy, Mid-sized Company, US
• Former Chief Business Officer, Mid-sized Company, Switzerland
• Chief Commercial Officer, Mid-sized Company, Switzerland
• President and Executive Director, Very Large Company, Japan
• Executive Director and Chief Scientific Officer, Very Large Company, Japan
• Chief Business Officer, Small Company, South Korea
• Former Vice President and Head of Chemistry, Mid-sized Company, US
• Vice President, Business Development, Small Company, Netherlands
• Former Director of CDMO, Very Large Company, France
• Former Director, Very Large Company, US
• Former Group Product Manager, Very Large Company, US
• Former Head of Bioconjugates Commercial Development, Very Large Company, Switzerland
• Former Site Head, Large Company, US
• General Manager, Large Company, Japan
• Professor, School of Medicine, Very Large Company, UK
• Director, Business Development, Leading CMO
• Chief Executive Officer, Leading CMO

Antibody drug conjugates domain will mark a turning point in 2026. Puja Sapra, (Senior Vice President, AstraZeneca), states, “We have deliberately made investment in the next-generation technologies which we believe will redefine oncology care, like ADCs [and] radioconjugates.”

Antibody Drug Conjugate Market Share Insights

Market Share by Target Indication: Antibody Drug Conjugates Targeting Breast Cancer Holds the Largest Share

• Based on the target indication, the global market is segmented into breast cancer, lung cancer, b-cell lymphoma, multiple myeloma, ovarian cancer, renal cancer, gastric cancer, Hodgkin's lymphoma and other target indications. Currently, therapies targeting breast cancer capture 44.7% of the overall antibody drug conjugate market share owing to the increasing prevalence of breast cancer.
• It is worth highlighting that the market for antibody drug conjugates targeting lung cancer is likely to grow at a higher CAGR and is anticipated to occupy a higher market share by the year 2035. Notably, in June 2025, the USFDA granted accelerated approval to TROP2 antibody-drug conjugate Datroway for the treatment of lung cancer.

Market Share by Therapeutics Area: Solid Tumor Sub-Segment Holds the Largest Share

• This segment highlights the distribution of market across various therapeutic areas, such as solid tumors and hematological cancer. Presently, solid tumor sub-segment captures the majority of the current (71%) and future (76%) market share.
• This can be attributed to the ongoing efforts of industry players in the development, approval and commercialization of ADC targeting solid tumors. Further, the increasing prevalence of solid tumors and the need for advanced ADC-based therapies is expected to drive antibody drug conjugate market growth.

Market Share by Linker: ADCs Conjugated with Tetrapeptide-based Linkers Holds the Largest Share

• According to the antibody drug conjugate market analysis, tetrapeptide-based linkers sub-segment captures majority of the current and future market share. This can be attributed to the fact that these linkers have shown great plasma stability and fast cleavage in the presence of intracellular proteases like cathepsin B.
• Interestingly, the antibody drug conjugate market for tetrapeptide-maleimide linkers sub-segment is expected to grow at a relatively faster pace (CAGR 65.7%) during the forecast period.

Antibody Drug Conjugate Market Segmentation by Payload Type

• This segment highlights the distribution of market across various payloads, such as monomethyl auristatin E (MMAE), camptothecin, exatecan, DM1, monomethyl auristatin F (MMAF), SN-38 / irinotecan, DM4 and other payloads. According to our projections, monomethyl auristatin E (MMAE) payload sub-segment captures the majority of the current (41%) and future (29%) market share within the antibody drug conjugate industry.
• It is worth mentioning in May 2025, the USFDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), a c-Met-directed antibody-drug conjugate using an MMAE payload, for adults with previously treated advanced non-squamous NSCLC with high c-Met protein overexpression.
• This can be attributed to MMAE’s exceptional picomolar-level cytotoxicity, which ensures high efficacy even at low concentrations. Further, MMAE's high membrane permeability enables it to diffuse into neighboring antigen-negative cells, thereby overcoming tumor heterogeneity.

Market Share by Target Antigens: HER-2 ADC Dominates the Market

• According to the antibody drug conjugate market forecast, therapies targeting HER-2 antigen sub-segment capture the majority of the current (48%) and future (40%) market share. This can be attributed to the overexpression of the HER-2 protein in various solid tumors, including breast and gastric cancers, which act as a biomarkers for targeted therapies. Interestingly, Roche’s Kadcyla was the first HER2 ADC to receive FDA approval in 2013, followed by Daiichi Sankyo / AstraZeneca’s Enhertu in 2019.
• It is worth highlighting that the market c-Met antigen sub-segment is anticipated to grow at a higher growth rate (CAGR of 41.8%) during the forecast period.

Antibody Drug Conjugate Market Analysis by Region: Asia-Pacific to Propel in the ADC Sector in the Coming Years

• North America is likely to capture the majority (62.3%) of the market share in the current year, according to our antibody drug conjugate market forecast, and this trend is unlikely to change in the future
• It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR (9.8%), during the forecast period. This is a result of the owing to the increasing number of biopharmaceutical startups in this region and the likely approval of multiple therapies in Asia-Pacific countries, including China and Australia.

Antibody Drug Conjugate Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Antibody Drug Conjugates Market Landscape Target Competitiveness Analysis Partnerships and Collaborations Funding and Investment Analysis Patent Analysis Grants Analysis Clinical Trials Analysis Combination Therapies KOL Analysis Success Protocol Analysis Market Sizing and Opportunity Analysis
Key ADC Companies Profiled	AbbVie ADC Therapeutics Astellas Pharma AstraZeneca Daiichi Sankyo Gilead Sciences GSK Jiangsu Hengrui Pharmaceuticals Kelun-Biotech Merck Pfizer Rakuten Medical RemeGen Roche (Full list of ~165 companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Antibody Drug Conjugate Market Major Takeaways

The “Antibody Drug Conjugate Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, target competitiveness analysis, partnerships and collaborations, funding and investment analysis, patent analysis, grants analysis, clinical trials analysis, combination therapies, KOL analysis, success protocol analysis and ADC market size and future opportunities within the antibody drug conjugates industry, during the forecast period.

Competitive Landscape of Antibody Drug Conjugate Therapies

Presently, close to 20 antibody drug conjugates have been commercialized for targeting various cancer indications. This is followed by therapy programs involving ADCs (46%) that are currently in the clinical stage of development; of these, majority therapy programs are in the late stages of development (phase II and above). Additionally, it is worth mentioning that close to 35% of the therapy programs involving ADCs (targeting hematological cancer) are in the early (pre-clinical and discovery) phases of development.

At present, six antibody drug conjugates have been approved for hematological malignancies in the US; these are Adcetris (Brentuximab Vedotin), Besponsa (Inotuzumab ozogamicin), Blenrep (Belantamab mafodotin), Mylotarg (Gemtuzumab ozogamicin), Polivy (Polatuzumab vedotin) and Zynlonta (Loncastuximab tesirine).

Competitive Landscape of Antibody Drug Conjugate Developers

The antibody drug conjugate market features the presence of close to 165 therapy developers. Further, the market is characterized by the presence of small players (43%), followed by mid-sized players (33%) and very large players (14%). It is worth mentioning that more than 35% of the players are headquartered in North America.

Further, in order to gain a competitive edge and establish a strong foothold in the industry, big pharma players are focusing on securing substantial investments for R&D and forging strategic partnerships to enhance their manufacturing capabilities. Notable examples of large players (ADC developers) headquartered in North America include (arranged in alphabetical order) Biocytogen, Exelixis and Takeda Oncology.

Market Size Analysis: What is the Opportunity for Antibody Drug Conjugates?

The global antibody drug conjugate market size is likely to be worth $ 18.69 billion in 2026 and will reach $ 28.41 billion by 2035. In terms of target indication, therapies targeting breast cancer capture 44.7% of the overall antibody drug conjugates market share owing to the increasing prevalence of breast cancer.

This domain presents a substantial and growing opportunity, undermined by rising cancer rates, strong research and development investment, expanding clinical pipelines, and supportive regulatory environments. Further, the adoption of combination therapies and the expansion of approved indications will further drive market growth.

Regional Analysis: Which Region Holds the Largest Share of the Antibody Drug Conjugates Market?

North America is Leading the Market

North American companies will likely dominate the global market in 2035, with 62% of ADC market share. This can be attributed to the fact that the USFDA has been actively reviewing and approving ADC therapeutics for cancer. Further, the rising incidence of cancer in the US is also contributing to the adoption of antibody drug conjugates.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is anticipated to grow at a faster pace (with a CAGR of 9.8%) in the foreseen future. Notable examples of mid-sized antibody drug conjugate companies based in Asia-Pacific with late stage (Phase III and above) ADCs in their pipeline, include Alphamab Oncology, CSPC Pharmaceutical, Daiichi Sankyo, DualityBio and Hengrui Pharma.

What are the Key Drivers of Antibody Drug Conjugate Market?

Recent advancements in biotechnology, including site-specific conjugation, novel next generation linker technologies, and innovative payloads, are enhancing ADC efficacy and safety, fueling innovation in targeted cancer therapies. Further, the rising prevalence of oncological disorders, with millions of new cases annually, is driving the increasing demand for precision medicine, particularly for oncology.

This demand is fueled by ADCs’ ability to deliver cytotoxic payloads directly to cancer cells, minimizing damage to healthy tissues. Coupled with increased R&D expenditure in the pharmaceutical industry, these factors are propelling the demand for ADCs. In addition, this surge is supporting the development of next-generation ADCs, addressing challenges like drug resistance and toxicity.

Key Market Trends in Antibody Drug Conjugate Market

Rising Partnerships and Collaborations Amongst the Drug Developers to Foster Progress and Innovation in Expanding their Capabilities

Antibody drug conjugates therapy developers have forged several partnerships with other stakeholders in order to develop and license ADCs and enhance their drug portfolios. It is worth highlighting that a significant rise in partnership activity was reported in 2026. Notably, the majority of the deals signed in this domain are instances of product licensing, followed by ADC technology licensing agreements. This can be attributed to the incessant efforts of drug developers to further enhance proprietary platforms and accelerate development across diverse therapeutic applications.

In March 2025, Roche partnered with Oxford BioTherapeutics to license two antibody-drug conjugates developed by Oxford BioTherapeutics. Under the terms of the agreement, the companies will jointly validate the therapeutic targets selected by Oxford BioTherapeutics, with Roche leading subsequent research and development efforts. Such partnerships are expected to drive market growth during the forecast period.

Antibody Drug Conjugate Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the antibody drug conjugates industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Market Landscape of Antibody Drug Conjugates Therapies
• Target Competitiveness Analysis
• Partnerships and Collaborations
• Funding and Investment Analysis
• Patent Analysis
• Grants Analysis
• Clinical Trials Analysis
• Combination Therapies
• KOL Analysis
• Success Protocol Analysis
• Company Profiles
• Key Commercialization Strategies
• Promotional Analysis
• A Case Study on Novel Conjugation and Linker Technology Platforms
• Cost Price Analysis
• A Case Study on Contract Manufacturing of Antibody Drug Conjugates
• A Case Study on Companion Diagnostics for Antibody Drug Conjugates
• Market Forecast Analysis

Frequently Asked Questions

Question 1: What are ADCs?

Answer: Antibody drug conjugates are a type of targeted cancer therapy that combines the specificity of monoclonal antibody with the small molecule (cytotoxic) drugs. ADCs are designed to selectively deliver a potent cytotoxic drug to cancer cells and minimize the toxic side effects associated with traditional chemotherapy.

Question 2: How big is the ADC market?

Answer: The antibody drug conjugates market is currently valued at USD 18.69 billion.

Question 3: Which region holds the highest antibody drug conjugate market share?

Answer: North America is currently leading the market with a share of 62%.

Question 4: What is the CAGR of antibody-drug conjugates market?

Answer: The market size for ADC is expected to grow at a compounded annual growth rate (CAGR) of 4.8% during the forecast period till 2035.

Question 5: What ADCs are on the market?

Answer: Currently 19 ADCs have been approved by various regulatory organizations for therapeutic use, across the globe, namely Adcetris, Aidixi, Akalux, Besponsa, Blenrep, Datroway, Elahere, Emrelis, Enhertu, Jiataile, Kadcyla, Lumoxiti, Mylotarg, Padcev, Polivy, Tivdak, Trastuzumab Rezetecan, Trodelvy and Zynlonta.

Question 6: What is the top selling antibody drug conjugate?

Answer: Enhertu is the top selling antibody-drug conjugate with sales revenues of around USD 3.75 billion in the year 2024.

Question 7: Who are the leading companies in the antibody drug conjugates market?

Answer: Leading companies in the ADC therapeutics market include AbbVie, ADC Therapeutics, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Jiangsu Hengrui Pharmaceuticals, Kelun-Biotech, Merck, Pfizer, Rakuten Medical, RemeGen and Roche.